10
Jun
2010
02
Jun
2010
Posted in I - Series C, Q - 2Q10, R - NORTH EAST, X - Antibacterial, X - Antiinfective, X - Pneumonia, X - UI, XX - MA
Tetraphase Pharmaceuticals (Watertown, MA) a clinical-stage biopharmaceutical company focused on broad spectrum antibiotics for the treatment of gram negative pathogens, unrinary tract infections and community acquired bacterial pneumonia, closed a $45M Series C financing. Participants include Excel Venture Management, CMEA Capital, Fidelity Biosciences, Flagship Ventures, Mediphase Venture Partners and Skyline Ventures.
19
Apr
2010
Posted in I - Series B, Q - 2Q10, R - INTERNATIONAL, X - Antibacterial, X - Antiinfective, X - Antiviral, X - CMV, X - HIV, X - Hepatitis B, X - Hepatitis C
AiCuris (Germany) a clinical-stage biopharmaceutical company focused on resistance breaking antiviral and antibacterial therapeutics targeting Human Cytomegalovirus, Herpes simplex, HIV, Hepatitis B and C and multi-resistant bacteria, closed a $74.8M Series B financing. Participants include Santo Holding and Bayer Healthcare.
27
Jan
2010
Posted in I - Series B, Q - 4Q09, R - NORTH EAST, X - Antiinfective, X - Asthma, X - COPD, X - Influenza, X - RSV, X - Respiratory, XX - MA
Pulmatrix (Lexington, MA) a clinical-stage biotechnology company focused on the discovery and development of therapies for the treatment and prevention of infectious (COPD, asthma, and cystic fibrosis) and progressive respiratory (influenza, ventilator acquired pneumonia and respiratory syncytial virus (RSV)) diseases, closed a $30.2M Series B financing. Participants include Arch Venture Partners, Novartis Ventures Funds,Polaris Venture [...]
17
Jan
2010
Posted in I - Series B, Q - 4Q09, R - INTERNATIONAL, X - Antiinfective, X - MRSA
Nabriva Therapeutics (Austria) a clinical-stage based developer of antibiotics for treating multi-drug resistant pathogens, closed a $22M Series B financing. Participants include Nomura Phase 4 Ventures, HBM Partners, Wellcome Trust, GLS Ventures and Novartis Venture Fund.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.
30
Oct
2009
Posted in I - Series C, Q - 3Q09, R - NORTH EAST, X - Antiinfective, X - Device (Diagnostic), XX - MA
PrimeraDx (Mansfield, MA) a development-stage molecular diagnostics company focused on automated multiplexed assays of infectious disease testing in immune compromised patients undergoing solid organ and bone marrow transplant, closed a $20M Series C financing. Participants include CHL Medical Partners, Abingworth, InterWest Partners, Malaysian Technology Development Corporation, MPM Capital, Burrill & Co. and Invus.
21
Oct
2009
20
Oct
2009
15
Sep
2009
06
Aug
2009